Exploring adverse neuropsychiatric effects of interferon alpha, using a preclinical model; exploring behavioural and pharmacological pathways to amelioration of these adverse effects

Recombinant Human Interferon-Alpha Pic from the Wikimedia Commons. Interferon alpha is widely used in the treatment of a variety of non-neurological conditions (for example, hepatitis C, Kaposi’s sarcoma, among others). It is in fact currently the only FDA-approved treatment for hepatitis C. Treatment for hepatitis is limited by the striking and adverse neuropsychiatric consequences of interferon alpha… Read More